Haemonetics (NYSE: HAE) reported Q1 EPS of $0.33, $0.02 better than the analyst estimate of $0.31. Revenue for the quarter came in at $211 million versus the consensus estimate of $212.12 million.

For earnings history and earnings-related data on Haemonetics (HAE) click here.